| Literature DB >> 25869102 |
Yunyun Jiang1, Joseph Ludwig2, Filip Janku3.
Abstract
The prognosis of adolescent and young adult patients battling metastatic Ewing sarcoma family of tumors (ESFT) remains less than 30% despite the development of systemic therapies. In the era of personalized medicine, novel molecular targets have been tested in preclinical or clinical settings in ESFT. In this review, we focus on early clinical and translational research that identified multiple molecular targets, including IGF-1R; mTOR; tyrosine kinase inhibitors; EWS-FLI1-related targets, and others. Overall, novel targeted therapies demonstrated modest efficacy; however pronounced and durable antineoplastic responses have been observed in small subsets of treated patients, for example with IGF-1R antibodies. Identifying outcome-predicting biomarkers and overcoming treatment resistance remain major challenges. Due to the rarity of ESFT, multi-institutional collaboration efforts of clinicians, basic and translational scientists are needed in order to understand biology of therapeutic response or resistance, which can lead to development of novel therapeutic methods and improved patient outcomes.Entities:
Keywords: Ewing sarcoma; Targeted therapies
Mesh：
Substances：
Year: 2015 PMID： 25869102 PMCID： PMC4426229 DOI： 10.1016/j.ctrv.2015.03.008
Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111